HC Wainwright Has Lowered Expectations for PDS Biotechnology (NASDAQ:PDSB) Stock Price

PDS Biotechnology (NASDAQ:PDSB) had its target price reduced by analysts at HC Wainwright from $21.00 to $13.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the stock.

PDS Biotechnology Trading Up 0.8 %

PDS Biotechnology stock opened at $1.26 on Thursday. The firm has a market capitalization of $48.12 million, a PE ratio of -1.09 and a beta of 1.68. The business’s 50-day simple moving average is $1.40 and its 200-day simple moving average is $2.16. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.84 and a current ratio of 2.84. PDS Biotechnology has a 52 week low of $1.13 and a 52 week high of $4.42.

PDS Biotechnology (NASDAQ:PDSB) last announced its earnings results on Thursday, March 27th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.08. Equities research analysts forecast that PDS Biotechnology will post -1.2 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Raymond James Financial Inc. acquired a new stake in PDS Biotechnology during the fourth quarter valued at approximately $26,000. Jane Street Group LLC bought a new position in PDS Biotechnology in the 4th quarter valued at $58,000. Marshall Wace LLP boosted its stake in PDS Biotechnology by 38.4% in the fourth quarter. Marshall Wace LLP now owns 39,024 shares of the company’s stock worth $64,000 after purchasing an additional 10,837 shares in the last quarter. Virtu Financial LLC acquired a new stake in shares of PDS Biotechnology in the fourth quarter valued at $89,000. Finally, Two Sigma Investments LP lifted its position in PDS Biotechnology by 273.5% during the 4th quarter. Two Sigma Investments LP now owns 65,732 shares of the company’s stock worth $107,000 after buying an additional 48,132 shares in the last quarter. 26.84% of the stock is owned by institutional investors.

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.